RESUMEN

Recombinant analogue of the sea anemone Heteractismagnifica peptide was obtained, and the kinetic parameters of its interaction with mammalian α-amylases were determined. Magnificamide inhibits α-amylases significantly stronger than the medical drug acarbose (PrecoseTM or GlucobayTM). Magnificamide is assumed to find application as a drug for prevention and treatment of metabolic disorders and type 2 diabetes mellitus.

Asunto(s)

Inhibidores Enzimáticos/farmacología , Péptidos/farmacología , alfa-Amilasas/antagonistas & inhibidores , Secuencia de Aminoácidos , Animales , Inhibidores Enzimáticos/química , Péptidos/química , Anémonas de Mar/química